Inclusion Criteria:

          -  Provision of fully informed consent prior to study specific procedures.

          -  Patients must be >= 19 years of age

          -  RET fusion positive or FGFR2 fusion/other FGFR mutation Refractory solid tumor and/or
             specific sensitivity to Sunitinib by Avatar scan that has progressed following
             standard therapy or that has not responded to standard therapy or for which there is
             no standard therapy.

          -  ECOG Performance status0-2

          -  Have measurable or evaluated disease based on RECIST 1.1 as determined by
             investigator.

          -  Adequate Organ Function Laboratory values

               -  Absolute neutrophil count >= 1.5 x 109/L, Hemoglobin >= 9g/dL, Platelets>=100 x
                  109/L Bilirubin <= 1.5 x upper limit of normal AST/ALT <= 2.5 X upper limit of
                  normal(5.0 x upper limit of normal, for subject with liver metastases)
                  Creatinine<= 1.5 X UNL

          -  Patients of child-bearing potential should be using adequate contraceptive measures
             should not be breast feeding and must have a negative pregnancy test prior to start of
             dosing

          -  Adequate heart function

        Exclusion Criteria:

          -  Patients with second primary cancer, except:adequately treated non-melanoma skin
             cancer, curatively treated in-situ cancer of the cervix, or other solid tumor
             curatively treated with no evidence of disease for <= 5 years.

          -  Has known active central nervous system(CNS) metastases

          -  Has an active infection requiring systemic therapy

          -  Pregnancy or breast feeding

          -  Patients with cardiac problem

          -  Any previous treatment with sunitinib